Novavax
United States
878 articles about Novavax
-
Novavax to Participate in TD Cowen's 44th Annual Health Care Conference
2/29/2024
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in TD Cowen's 44th Annual Health Care Conference.
-
Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
2/28/2024
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2023.
-
The vaccine maker’s fourth-quarter revenue and earnings on Wednesday missed Wall Street expectations, while providing full-year 2024 sales guidance of flat to lower than last year.
-
The settlement, which includes an upfront $75 million payment to Gavi, ends arbitration related to a 2021 advance purchase agreement involving Novavax’s prototype vaccine NVX-CoV2373.
-
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024
2/20/2024
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2023 financial results and operational highlights at 8:30 a.m. Eastern Standard Time (EST) on Wednesday, February 28, 2024.
-
Novavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
1/3/2024
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the 42th Annual J.P. Morgan Healthcare Conference.
-
Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan
12/18/2023
Novavax, Inc. announced that the Taiwan Food and Drug Administration has granted emergency use authorization for Nuvaxovid™ XBB.1.5 dispersion for injection COVID-19 Vaccine for active immunization to prevent COVID-19 in individuals aged 12 and older.
-
Novavax's Updated COVID-19 Vaccine Now Authorized in Canada
12/5/2023
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Health Canada has granted expanded authorization for Nuvaxovid™ XBB.1.5 Vaccine (Recombinant protein, Adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older.
-
Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization
11/28/2023
Novavax, Inc. announced that Nuvaxovid™ XBB.1.5 COVID-19 Vaccine has been granted Emergency Use Listing by the World Health Organization for active immunization to prevent COVID-19 in individuals aged 12 and older.
-
Novavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic Priorities
11/17/2023
Novavax, Inc. today announced changes to its executive leadership team designed to enhance focus on its strategic priorities and continue the evolution of the Company's scale and structure announced last week.
-
Novavax and R.A. Miller Industries receive the 2023 "Tell Award" for their business investments in Switzerland
11/15/2023
Novavax and R.A. Miller Industries, two American companies at the forefront of innovation, have each won a 2023 Tell Award from the Swiss authorities, recognizing their significant foreign direct investment in Switzerland, reports Daniel Bangser, Trade Commissioner of Switzerland.
-
Novavax to Participate in Jefferies 2023 London Healthcare Conference
11/10/2023
Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, announced that it will participate in the Jefferies London Healthcare Conference.
-
Novavax Reports Third Quarter 2023 Financial Results and Operational Highlights
11/9/2023
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced its financial results and operational highlights for the third quarter ended September 30, 2023.
-
The vaccine maker is prepared to cut another $300 million in operating expenses in 2024 to keep the company afloat as it works to get its combination COVID-19/flu vaccine into Phase III.
-
Novavax to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Operational Highlights on November 9, 2023
11/2/2023
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its third quarter 2023 financial results and operational highlights at 8:30 a.m. Eastern Standard Time (EST) on Thursday, November 9, 2023.
-
Novavax's Updated COVID-19 Vaccine Now Approved in the EU
10/31/2023
Novavax, Inc. (Nasdaq: NVAX) today announced the European Commission has granted approval for Nuvaxovid™ XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older.
-
Novavax's Updated Nuvaxovid™ COVID-19 Vaccine Receives Positive CHMP Opinion in the EU
10/31/2023
Novavax, Inc. (Nasdaq: NVAX) today announced that the Nuvaxovid™ XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) has been recommended for approval for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older in the European Union by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency.
-
Novavax's Prototype COVID-19 Vaccine Nuvaxovid™ Receives Full Approval in Singapore
10/18/2023
Novavax, Inc. today announced that Singapore's Health Sciences Authority (HSA) has granted full approval for Novavax's prototype COVID-19 vaccine Nuvaxovid™ (NVX-CoV2373) for active immunization to prevent COVID-19 in individuals aged 12 and older.
-
Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ in United Kingdom
10/18/2023
Novavax, Inc. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.
-
Novavax COVID-19 Vaccine Doses Available at Major Retail Pharmacies Across the U.S.
10/13/2023
Novavax, Inc. (Nasdaq: NVAX) today announced that it has finalized agreements with major pharmacy retailers and prominent Group Purchasing Organizations (GPO) in the U.S. to provide the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) to prevent COVID-19 in individuals aged 12 and older this vaccination season.